Ascentage Pharma Group International (HK:6855)
:6855
Want to see HK:6855 full AI Analyst Report?
Top Page
Ascentage Pharma Group International
(6855)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$37.00
▼(-27.31% Downside)
Action:Reiterated
Date:05/04/26
The score is held back primarily by continued heavy losses and accelerating cash burn, despite strong revenue growth and high gross margins. Technicals also remain weak with the stock trading below key moving averages and negative momentum; valuation support is limited given negative earnings and no dividend.
Positive Factors
Accelerating Revenue Growth
Revenue accelerated ~43% in 2025, indicating stronger commercial traction or milestone-driven income. A growing top line improves the company’s ability to fund R&D, attract partners, and sustain multi-year clinical programs, supporting business durability beyond short cycles.
Negative Factors
Intense Cash Burn
Large negative operating and free cash flows in 2025 show accelerating cash burn, increasing dependence on external financing. Over the coming months this elevates funding risk, could force dilution or program prioritization, and constrains long-term self-funding of trials.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue accelerated ~43% in 2025, indicating stronger commercial traction or milestone-driven income. A growing top line improves the company’s ability to fund R&D, attract partners, and sustain multi-year clinical programs, supporting business durability beyond short cycles.
Read all positive factors
Ascentage Pharma Group International (6855) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.91B
Dividend YieldN/A
Average Volume (3M)2.29M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-41.32%
EPS Growth-159.81%
CountryHK
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.46
Shares Outstanding373,334,750
10 Day Avg. Volume1,948,642
30 Day Avg. Volume2,293,783
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$80.10Price Target Upside57.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.79
Revenue Forecast (FY)HK$920.49M
Ascentage Pharma Group International Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP13...
How the Company Makes Money
null...
Ascentage Pharma Group International Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 559.26M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 427.35M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.10B | -299.63M | -743.61M | -835.99M | -915.99M |
| Net Income | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | |||||
| Total Assets | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.26B | 1.10B | 1.50B | 1.75B |
| Total Debt | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.20B | -135.65M | -782.92M | -857.20M | -1.04B |
| Operating Cash Flow | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Technical Analysis
Negative
50.90
Price Trends
45.83
Negative
47.97
Negative
60.21
Negative
Market Momentum
-2.44
Positive
26.54
Positive
11.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6855, the sentiment is Negative. The current price of 50.9 is above the 20-day moving average (MA) of 43.52, above the 50-day MA of 45.83, and below the 200-day MA of 60.21, indicating a bearish trend. The MACD of -2.44 indicates Positive momentum. The RSI at 26.54 is Positive, neither overbought nor oversold. The STOCH value of 11.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6855.
Ascentage Pharma Group International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$38.32B | ― | 25.67% | ― | 16.65% | 0.87% | |
63 Neutral | HK$17.95B | 50.10 | 10.12% | ― | 110.05% | ― | |
53 Neutral | HK$10.91B | ― | -10.55% | ― | 142.64% | 72.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$39.22B | -256.36 | -10.78% | ― | 34.19% | 47.97% | |
44 Neutral | HK$13.91B | -6.78 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:6855
Ascentage Pharma Group International
37.70
-6.55
-14.80%
HK:9969
InnoCare Pharma Ltd.
12.06
1.46
13.77%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
22.60
6.92
44.13%
HK:1952
Everest Medicines Ltd.
30.66
-13.64
-30.79%
HK:2096
Simcere Pharmaceutical Group Limited
11.00
1.34
13.87%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
70.70
30.15
74.35%
Ascentage Pharma Group International Corporate Events
Ascentage Pharma Adds Executive Equity Grants to AGM Agenda and Updates Proxy Process
Apr 30, 2026
Ascentage Pharma Group International has issued a supplemental notice confirming that its annual general meeting will proceed as scheduled in Suzhou on May 20, 2026, while adding two new ordinary resolutions. Shareholders will be asked to approve ...
Ascentage Pharma Sets AGM to Approve 2025 Accounts, Board Mandates and Share Issue Authority
Apr 28, 2026
Ascentage Pharma Group International has called its annual general meeting for May 20, 2026, in Suzhou, China, where shareholders will vote on key corporate matters, including adoption of the 2025 audited financial statements and reports. The meet...
Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting
Apr 21, 2026
Ascentage Pharma will present data from six clinical studies involving three key drug candidates at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, underscoring the company’s growing presence in cutting-edge cancer ...
Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme
Apr 20, 2026
Ascentage Pharma has granted 696,263 restricted share units under its 2022 RSU Scheme to three senior personnel, including CEO and executive director Dr. Yang Dajun, chief medical officer and substantial shareholder Dr. Zhai Yifan, and a senior ma...
Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026
Apr 19, 2026
Ascentage Pharma Group International will present four preclinical studies at the American Association for Cancer Research 2026 Annual Meeting, highlighting three key drug candidates: olverembatinib, APG-2449, and APG-5918. The data underscore the...
Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards
Apr 1, 2026
Ascentage Pharma Group International has changed its principal place of business in Hong Kong to Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, effective April 1, 2026. The move, approved and announced by the board of directors, may ...
Ascentage Pharma Ramps Up Sales, Dual Listing and Late-Stage Oncology Pipeline in 2025
Mar 25, 2026
Ascentage Pharma reported a 90% year-on-year increase in 2025 product sales and commercial rights revenue to RMB574.1 million, driven by strong growth of its leukemia drug Olverembatinib and the launch of Lisaftoclax in China. The company also str...
Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting
Mar 18, 2026
Ascentage Pharma will present new preclinical data on four studies from its oncology pipeline at the 2026 American Association of Cancer Research Annual Meeting in San Diego. The presentations highlight promising combination strategies for its BCR...
Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 13, 2026
Ascentage Pharma Group International has scheduled a board meeting for March 25, 2026, to review and approve the group’s annual results for the financial year ended December 31, 2025. The board will also consider the declaration of a final d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.